Targeting part of an antiviral pathway triggered by the accumulation of a key pathogen shared in Alzheimer's disease and frontotemporal dementia may one day offer a new therapeutic approach to deterring or delaying cognitive decline, according to preclinical research led by Weill Cornell Medicine scientists.
The 10th annual Appel Alzheimer's Disease Research Institute Symposium brought fascinating reports of progress in understanding Alzheimer's and related neurodegenerative diseases.
New Developments in Dementia Research Presented at Appel Alzheimer's Disease Research Institute Symposium cornell.edu - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from cornell.edu Daily Mail and Mail on Sunday newspapers.
Reprogramming the Brain's Cleaning Crew to Mop Up Alzheimer's Disease | Newsroom cornell.edu - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from cornell.edu Daily Mail and Mail on Sunday newspapers.
Inhibiting an important signaling pathway in brain-resident immune cells may calm brain inflammation and thereby slow the disease process in Alzheimer’s and some other neurodegenerative diseases, a study by Weill Cornell Medicine investigators suggests.